Account
Inquiry
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This innovative peptide demonstrates superior efficacy in glucose control and weight management compared to single-receptor agonists.
Our pharmaceutical-grade Tirzepatide is supplied as white powder in sterile vials with 99.9% purity. The product shows significantly better efficacy regarding glucose control and weight loss than selective GLP-1 receptor agonists. Tirzepatide has greater affinity to GIP receptors while maintaining GLP-1 receptor activity.
Clinical studies demonstrate Tirzepatide's weight loss potential, with average reductions of 15-20.9% body weight at different dosages over 72 weeks. The peptide has received FDA Fast Track designation for obesity treatment research.
The molecular structure features a PEG-modified lysine side chain that enhances water solubility. This modification contributes to the peptide's extended half-life and weekly dosing potential in research settings.
For research use only. Not for human consumption. Proper storage in cool, dry conditions is essential to maintain peptide stability. Avoid repeated freeze-thaw cycles and light exposure.
